Protalix BioTherapeutics reported financial results for the second quarter ended June 30, 2026, achieving profitability with a net income of $3.8 million for the quarter and $22.1 million year-to-date. Total revenue for the first half of 2026 climbed to $53.6 million, significantly up from $25.8 million in the prior ye...

Reviva Pharmaceuticals reported financial results for the second quarter ended June 30, 2026. The company reported a net loss of $2.4 million ($0.19 per share), a significant reduction from the $6.1 million loss in the prior year period. Cash and cash equivalents stood at $19.9 million as of June 30, 2026. Key busine...

RenovoRx, Inc. (Nasdaq: RNXT) reported record financial results for the second quarter ended June 30, 2026. Quarterly revenue reached $909,000, representing a 61% sequential increase from Q1 2026 and 115% growth year-over-year. This performance was driven by the commercial adoption of the RenovoCath drug-delivery devic...

Sangamo Therapeutics, Inc. filed a Current Report on Form 8-K to provide updates regarding its ongoing Chapter 11 bankruptcy proceedings, which commenced on June 23, 2026, in the United States Bankruptcy Court for the District of Delaware (Case No. 26-10989). On August 6, 2026, the company filed its Monthly Operating R...

Spruce Biosciences reported second quarter 2026 financial results and provided a major corporate update regarding its lead candidate, tralesinidase alfa (TA-ERT), for the treatment of MPS IIIB. The company anticipates submitting a Biologics License Application (BLA) for TA-ERT in the fourth quarter of 2026, seeking acc...